Cs-131 Brachytherapy for Recurrent Brain Cancer
May 7, 2018 | Technology Forecasts
Note: The following ratings and comments reflect the opinions and consensus of an expert panel convened by ECRI Institute to review information on this topic.
Anticipated Utilization: 1(Expected to be used by <20% of eligible patients)
The manufacturer of Cs-131 seeds and GammaTile™ (GT Medical Technologies, Inc., Mesa, AZ, USA, and IsoRay, Inc., Richland, WA, USA) estimates that about 175,000 patients could be candidates for this type of brachytherapy. Patient acceptance would likely be high if additional studies can confirm early reports of improved quality of life from preliminary studies.
Estimated Adoption Status: 2 (Early adoption expected in 0 to 2 years)
IsoRay, Inc. (Richland, WA, USA) received a response letter from FDA on July 6, 2017, requiring additional data regarding GammaTile’s 510(k) application. FDA requires the data within 180 days of notification as a condition of securing FDA clearance for the GammaTile device. GammaTile might be available for use in 2018. If approved, adoption could be very slow or...